MEK could also be a potential therapeutic target, as its specific MEK inhibitor PD184352, when combined with BMS-214662 increased apoptosis in TKI-unresponsive CD34+ CML cells [61]. The gene discussed is MAP2K7; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.